Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary Abnormalities
Healthy, Pituitary Disease, Thyroid Disease
ClinicalTrials.gov recordTREATMENT READING
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
Source: Pituitary Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 17, 2024. Captured 2026-09-09.
The goals of treatment of pituitary adenomas include normalization of hormonal secretion (i.e., normalization of hypersecretion and improvement in hypofunction) and resolution or cessation of the progression of neurological defects.
Treatment options for patients with pituitary tumors include:
Surgery.
Radiation therapy.
Medical therapy.
A combination of surgery, radiation therapy, and medical therapy.
Stereotactic radiation surgery (under clinical evaluation).[1]
Sources: 1
The choice of treatment must be individualized and is dictated by the type of tumor, the nature of the excessive hormonal expression, and whether the tumor extends into the brain around the pituitary.[2,3]
The transsphenoidal microsurgical approach to a pituitary lesion is the most widely used approach and represents a major development in the safe surgical treatment of both hormonally active and nonfunctioning tumors.[4-6] This approach is often successful in debulking tumors, even those that have a significant suprasellar extension.
This surgery is contraindicated in patients with tumors with a significant suprasellar extension and an hourglass-shaped narrowing between the intrasellar and suprasellar component because blind attempts to reach the suprasellar tumor may lead to cerebral damage. In addition, an infection in the sphenoid sinus is a potential contraindication to the transsphenoidal approach. In such cases, craniotomies via a pterional or subfrontal approach may be performed. Rapid deterioration of vision is an immediate indication for surgery to relieve pressure produced by an expanding tumor mass, except in the case of macroprolactinomas (where intensive observation with a patient on dopaminergic agonists may be an acceptable alternative). Progressive deterioration of visual fields is often the primary neurological criterion on which surgical management decisions are based.[7]
Sources: 7
Conventional radiation therapy is an effective adjunct to the treatment of pituitary tumors.[4] The advantages of radiation therapy are that it is noninvasive and suitable for surgically high-risk patients. The clinical and biochemical response, however, is slow and may require from 2 to 10 years for complete and sustained remission. In addition, radiation therapy carries a substantial risk of hypopituitarism (i.e., approximately 30% at 10 years).
Sources: 4
Hormone-secreting tumors may be treated with surgery or radiation therapy. Surgical therapy is the treatment of choice for growth hormone (GH)-producing, adrenocorticotropic hormone (ACTH)-producing, and endocrine-inactive adenomas. GH-secreting tumors can be treated with somatostatin analogues, dopamine analogues, and GH-receptor antagonists, such as pegvisomant.[7] Ketoconazole, an inhibitor of steroidogenesis, is considered the first drug of choice as adjuvant therapy for ACTH-producing tumors.[4] Somatostatin analogues are the treatment of choice for thyroid-stimulating hormone-producing adenomas, but their efficacy may wane with time.[7]
The natural history of GH-secreting and ACTH-secreting pituitary tumors is usually one of slowly progressive enlargement.[4] Microprolactinomas, however, often remain unchanged, or decrease in size over time, and they have occasionally been observed to undergo complete, spontaneous resolution.[7]
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Source: Pituitary Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 17, 2024. Captured 2026-09-09.
Source: Pituitary Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 17, 2024. Captured 2026-09-09.
Treatment options for PRL-producing pituitary tumors include:
When the pituitary tumor secretes PRL, treatment depends on tumor size and the symptoms that result from excessive hormone production. Patients with PRL-secreting tumors are treated with surgery and radiation therapy.[1]
Sources: 1
Most microprolactinomas and macroprolactinomas respond well to medical therapy with ergot-derived dopamine agonists, including bromocriptine and cabergoline.[2] For many patients, cabergoline has a more tolerable side effect profile than bromocriptine. Cabergoline therapy may be successful in treating patients whose prolactinomas are resistant to bromocriptine or who cannot tolerate bromocriptine, and this treatment has a success rate of more than 90% in patients with newly diagnosed prolactinomas.[3-5] In a prospective study, cabergoline was safely withdrawn in patients with normalized PRL levels and no evidence of tumor, which may produce a cure rate of approximately 70%.[6] Bromocriptine is the treatment of choice when the patient wants to preserve fertility because of its safety record in pregnancy.[7]
Microprolactinomas change little in size with treatment, but macroprolactinomas can shrink, sometimes quite dramatically. Microprolactinomas may decrease in size over time and they have occasionally been observed to undergo complete, spontaneous resolution.[8] Surgery is typically reserved for patients who cannot tolerate dopamine agonists, who suffer pituitary apoplexy during treatment, or whose macroprolactinomas are not responsive to medical therapy.[2] Occasionally, these tumors may require radiation therapy.[9]
Source: Pituitary Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 17, 2024. Captured 2026-09-09.
Source: Pituitary Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 17, 2024. Captured 2026-09-09.
Treatment options for ACTH-producing pituitary tumors include:
Steroidogenesis inhibitors, including mitotane, metyrapone, ketoconazole, and aminoglutethimide.[1,2,5]
Transsphenoidal microsurgery is the treatment of choice for patients with corticotroph adenomas.[1,2] Most series report remission rates of approximately 70% to 90%.[1] In a series of 216 patients who underwent surgery using a transsphenoidal approach, 75% experienced long-term remission, 21% experienced persistence of Cushing disease, and 9% had recurrence after the initial correction of the hypercortisolism.[3] The average time interval for reoperation was 3.8 years. Seventy-nine percent of the tumors were microadenomas, and 18% were macroadenomas; 86% of the cases with microadenoma had long-term remission, compared with only 46% of those with macroadenoma. In cases in which hypercortisolemia persists, early repeat exploration and/or radiation therapy or laparoscopic bilateral adrenalectomy may be required.[2]
Radiation therapy has been used in patients who are not surgical candidates and has also been used as adjuvant therapy in patients with residual or recurrent active tumor.[1,4]
Drug therapy may be an adjunct to transsphenoidal microsurgery in cases of residual tumor and in cases where radiation therapy has a delayed effect.[1] Steroidogenesis inhibitors, including mitotane, metyrapone, ketoconazole, and aminoglutethimide are used. Ketoconazole is the best tolerated of these agents and is effective as monotherapy in about 70% of patients.[5]
If untreated, patients frequently die of cardiovascular disease or infection.
Source: Pituitary Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 17, 2024. Captured 2026-09-09.
Source: Pituitary Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 17, 2024. Captured 2026-09-09.
Treatment options for GH-producing pituitary tumors include:
Surgery (usually a transsphenoidal approach).
Dopamine analogues, such as bromocriptine.
Somatostatin analogues, such as octreotide.
Surgery and postoperative radiation therapy.
Treatment for patients with acromegaly includes surgical, radiation, and medical therapies.[3] Treatment depends on the size and extent of the tumor and the need for rapid cessation of hormone function that results in serious clinical sequelae (i.e., hypertension and cardiomyopathy).
Sources: 3
Microadenomectomy or macroadenoma decompression is approached transsphenoidally in most patients. Increasingly, endoscopic surgery is used to allow the entire surgical field to be viewed and to allow tumor tissue that would otherwise be inaccessible with rigid instruments to be safely resected. However, normalization of GH levels is not often achieved. Increasingly, adjuvant radiation therapy is reserved for tumors that extend beyond the safe operative area and appear to pose an ongoing threat.
Drug treatment, whether used as an adjuvant or primary therapy in appropriately selected patients,[4] includes the use of somatostatin analogues, such as octreotide; dopamine analogues, such as bromocriptine; and, the GH-receptor antagonist pegvisomant. As the first of a new class of GH-receptor antagonists, pegvisomant works by inhibiting functional dimerization of GH receptors, inhibiting GH action. Results indicate that it may be the most effective medical treatment for acromegaly.[1,2]
In acromegalic patients, impaired glucose tolerance, hypertension, and hyperlipidemia should be vigorously treated concurrently with definitive therapy. A multidisciplinary clinical approach may be required for the treatment of arthritis, carpal tunnel syndrome, obstructive sleep apnea, and prognathism.[5] Mortality is related primarily to cardiovascular and respiratory diseases.[5]
Source: Pituitary Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 17, 2024. Captured 2026-09-09.
Source: Pituitary Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 17, 2024. Captured 2026-09-09.
Treatment options for thyrotropin-producing tumors include:
Surgery (usually a transsphenoidal approach), with or without adjuvant radiation therapy.[1,2]
Transsphenoidal surgery is the treatment of choice for patients with thyrotropic adenomas.[1] Adjuvant radiation therapy may be used when surgery is known to be noncurative, even if the patient is still euthyroid. This is because relapse is inevitable, and the full effect of radiation therapy requires months or years.
Sources: 1
Source: Pituitary Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 17, 2024. Captured 2026-09-09.
Source: Pituitary Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 17, 2024. Captured 2026-09-09.
Treatment options for nonfunctioning pituitary tumors include:
Surgery (preferably with a transsphenoidal approach) followed by close observation with radiation therapy reserved for recurrence.[1,2]
Treatment selection for patients with nonfunctioning (endocrine-inactive) tumors depends on tumor size, the progressive course of the disease, and anatomical structures affected by the tumor extension. Most patients present with suprasellar extension and visual field deficits. In addition, many have hormone deficits before treatment. The initial treatment of patients with gonadotroph adenomas is usually by transsphenoidal surgery, particularly if the adenoma presents with neurological symptoms. This is because the effect of radiation therapy occurs too slowly, and no reliable medical therapy exists.[4]
Sources: 4
The first choice of treatment for patients with endocrine-inactive pituitary adenomas is usually surgery, which ameliorates symptoms of chiasmal compression and headache.[1] However, radical removal of the tumor is difficult because of frequent invasion into the cavernous sinus. Seventy percent to 80% of patients experience normalization or improvement of visual field defects, and almost 100% of patients with headache as a presenting symptom experience relief. Regrowth of the tumor after radiologically confirmed gross total removal appears to be uncommon. In a series of 32 patients, only 2 (6.2%) with gross total tumor removal and no postoperative radiation therapy showed radiological recurrence of the tumor at a mean follow-up of 5.5 years.[5]
Source: Pituitary Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 17, 2024. Captured 2026-09-09.
Source: Pituitary Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 17, 2024. Captured 2026-09-09.
Treatment options for pituitary carcinomas include:
Surgery.
Dopamine agonists, such as bromocriptine, pergolide, quinagolide, and cabergoline, for prolactin (PRL)-producing carcinomas.
Somatostatin analogues, such as octreotide, for growth hormone (GH)–producing and thyroid-stimulating hormone (TSH)-producing carcinomas.
Adjuvant radiation therapy, which does not appear to change outcome.
Chemotherapy, which is of little benefit.
Some reports indicate that as many as 88% of pituitary carcinomas are endocrinologically active, and adrenocorticotrophin hormone-secreting tumors are the most common.[1] Treatments for patients with pituitary carcinomas are palliative, with the mean survival time ranging from 2 to 2.4 years, though several case reports of long-term survivors have been published.[2-5]
Treatment options for patients with pituitary carcinomas include resection and dopamine agonists for PRL-producing tumors; somatostatin analogues for GH-producing and TSH-producing tumors; radiation therapy, and chemotherapy.[1]
Sources: 1
Source: Pituitary Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 17, 2024. Captured 2026-09-09.
Source: Pituitary Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 17, 2024. Captured 2026-09-09.
Treatment options for recurrent pituitary tumors include:
Radiation therapy for postsurgical recurrence, which offers a high likelihood of local control.[1,2]
Reirradiation, which provides long-term local control and control of visual symptoms.[3]
Sources: 3
Treatment for patients with relapsed disease depends on many factors, including the specific type of pituitary tumor, previous treatment, visual and hormonal complications, and individual patient considerations.
Source: Pituitary Tumors Treatment, National Cancer Institute.
Source updated: March 28, 2025. Captured 2026-09-09.
Different types of treatments are available for patients with pituitary tumors. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment. Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.
Sources: pituitary tumors · clinical trials · research study
Source: Pituitary Tumors Treatment, National Cancer Institute.
Source updated: March 28, 2025. Captured 2026-09-09.
Treatment options for pituitary tumors
The following types of treatment are used:
Source: Pituitary Tumors Treatment, National Cancer Institute.
Source updated: March 28, 2025. Captured 2026-09-09.
Many pituitary tumors can be removed by surgery using one of the following operations:
Sources: surgery
Transsphenoidal surgery: A type of surgery in which the instruments are inserted into part of the brain by going through an incision (cut) made under the upper lip or at the bottom of the nose between the nostrils and then through the sphenoid bone (a butterfly-shaped bone at the base of the skull) to reach the pituitary gland. The pituitary gland lies just above the sphenoid bone.
Sources: Transsphenoidal surgery · brain · incision · sphenoid bone · skull · pituitary gland
Endoscopic transsphenoidal surgery: A type of surgery in which an endoscope is inserted through an incision (cut) made at the back of the inside of the nose and then through the sphenoid bone to reach the pituitary gland. An endoscope is a thin, tube-like instrument with a light, a lens for viewing, and a tool for removing tumor tissue.
Sources: Endoscopic · endoscope · lens · tumor · tissue
Craniotomy: Surgery to remove the tumor through an opening made in the skull.
Sources: Craniotomy
After the doctor removes all the cancer that can be seen at the time of the surgery, some patients may be given chemotherapy or radiation therapy after surgery to kill any cancer cells that are left. Treatment given after the surgery, to lower the risk that the cancer will come back, is called adjuvant therapy.
Sources: chemotherapy · radiation therapy · cells · adjuvant therapy
Source: Pituitary Tumors Treatment, National Cancer Institute.
Source updated: March 28, 2025. Captured 2026-09-09.
Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. External radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer. Certain ways of giving radiation therapy can help keep radiation from damaging nearby healthy tissue. This type of radiation therapy may include:
Sources: x-rays · radiation · External radiation therapy
Stereotactic radiosurgery: A rigid head frame is attached to the skull to keep the head still during the radiation treatment. A machine aims a single large dose of radiation directly at the tumor. This procedure does not involve surgery. It is also called stereotaxic radiosurgery, radiosurgery, and radiation surgery.
Sources: Stereotactic radiosurgery · dose
Source: Pituitary Tumors Treatment, National Cancer Institute.
Source updated: March 28, 2025. Captured 2026-09-09.
Source: Pituitary Tumors Treatment, National Cancer Institute.
Source updated: March 28, 2025. Captured 2026-09-09.
Chemotherapy may be used as palliative treatment for pituitary carcinomas, to relieve symptoms and improve the patient's quality of life. Chemotherapy uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy). When chemotherapy is placed directly into the cerebrospinal fluid, an organ, or a body cavity such as the abdomen, the drugs mainly affect cancer cells in those areas (regional chemotherapy). The way the chemotherapy is given depends on the type of the cancer being treated.
Sources: palliative treatment · carcinomas · symptoms · quality of life · injected · vein · systemic chemotherapy · cavity · abdomen · regional chemotherapy
Source: Pituitary Tumors Treatment, National Cancer Institute.
Source updated: March 28, 2025. Captured 2026-09-09.
Treatment of nonfunctioning pituitary tumors
Treatment may include:
Surgery (transsphenoidal surgery, if possible) to remove the tumor, followed by watchful waiting (closely monitoring a patient’s condition without giving any treatment until signs or symptoms appear or change). Radiation therapy is given if the tumor comes back.
Sources: Surgery · transsphenoidal surgery · tumor · watchful waiting · monitoring · condition · signs · symptoms · Radiation therapy
Radiation therapy alone.
Treatment for luteinizing hormone–producing and follicle-stimulating hormone–producing tumors is usually transsphenoidal surgery to remove the tumor.
Sources: luteinizing hormone · follicle-stimulating hormone
Source: Pituitary Tumors Treatment, National Cancer Institute.
Source updated: March 28, 2025. Captured 2026-09-09.
Treatment of prolactin-producing pituitary tumors
Treatment may include:
Drug therapy to stop the tumor from making prolactin and to stop the tumor from growing.
Sources: Drug therapy · tumor · prolactin
Surgery to remove the tumor (transsphenoidal surgery or craniotomy) when the tumor does not respond to drug therapy or when the patient cannot take the drug.
Sources: Surgery · transsphenoidal surgery · craniotomy · respond · drug
Radiation therapy.
Sources: Radiation therapy
Surgery followed by radiation therapy.
Source: Pituitary Tumors Treatment, National Cancer Institute.
Source updated: March 28, 2025. Captured 2026-09-09.
Treatment of adrenocorticotropic hormone (ACTH)–producing pituitary tumors
Treatment may include:
Surgery (usually transsphenoidal surgery) to remove the tumor, with or without radiation therapy.
Sources: Surgery · transsphenoidal surgery · tumor · radiation therapy
Radiation therapy alone.
Drug therapy to stop the tumor from making ACTH.
Sources: Drug therapy · ACTH
A clinical trial of stereotactic radiation surgery.
Sources: clinical trial · stereotactic radiation surgery
Source: Pituitary Tumors Treatment, National Cancer Institute.
Source updated: March 28, 2025. Captured 2026-09-09.
Treatment of growth hormone–producing pituitary tumors
Treatment may include:
Surgery (usually transsphenoidal or endoscopic transsphenoidal surgery) to remove the tumor, with or without radiation therapy.
Sources: Surgery · transsphenoidal · endoscopic · tumor · radiation therapy
Drug therapy to stop the tumor from making growth hormone.
Sources: Drug therapy · growth hormone
Source: Pituitary Tumors Treatment, National Cancer Institute.
Source updated: March 28, 2025. Captured 2026-09-09.
Treatment of thyroid-stimulating hormone–producing tumors
Treatment may include:
Surgery (usually transsphenoidal surgery) to remove the tumor, with or without radiation therapy.
Sources: Surgery · transsphenoidal surgery · tumor · radiation therapy
Drug therapy to stop the tumor from making hormones.
Sources: Drug therapy · hormones
Source: Pituitary Tumors Treatment, National Cancer Institute.
Source updated: March 28, 2025. Captured 2026-09-09.
Treatment of pituitary carcinomas
Treatment of pituitary carcinomas is palliative, to relieve symptoms and improve the quality of life. Treatment may include:
Sources: carcinomas · palliative · symptoms · quality of life
Surgery (transsphenoidal surgery or craniotomy) to remove the cancer, with or without radiation therapy.
Sources: Surgery · transsphenoidal surgery · craniotomy · radiation therapy
Drug therapy to stop the tumor from making hormones.
Sources: Drug therapy · tumor · hormones
Chemotherapy.
Sources: Chemotherapy
Source: Pituitary Tumors Treatment, National Cancer Institute.
Source updated: March 28, 2025. Captured 2026-09-09.
Treatment of recurrent pituitary tumors
Treatment may include:
Radiation therapy.
Sources: Radiation therapy
A clinical trial of stereotactic radiation surgery.
Sources: clinical trial · stereotactic radiation surgery
Source: Pituitary Tumors Treatment, National Cancer Institute.
Source updated: March 28, 2025. Captured 2026-09-09.
Clinical trials
For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment.
Sources: clinical trial · standard treatment
Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment.
Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.
Source: Pituitary Tumors Treatment, National Cancer Institute.
Source updated: March 28, 2025. Captured 2026-09-09.
Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.
Clinical trials are taking place in many parts of the country. Find clinical trials for pituitary tumors at Clinical Trials to Treat Pituitary Tumors. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website. General information about clinical trials is also available.
Sources: Clinical Trials to Treat Pituitary Tumors · ClinicalTrials.gov · General information
Source: Pituitary Tumors Treatment, National Cancer Institute.
Source updated: March 28, 2025. Captured 2026-09-09.
Side effects of treatment
Treatment for pituitary tumors may cause side effects. For information about side effects caused by treatment for cancer, visit our Side Effects page.
Sources: Side Effects
Source: Pituitary Tumors Treatment, National Cancer Institute.
Source updated: March 28, 2025. Captured 2026-09-09.
Follow-up care
As you go through treatment, you will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.
Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back).
Healthy, Pituitary Disease, Thyroid Disease
ClinicalTrials.gov recordCushing's Syndrome
ClinicalTrials.gov recordCushing's Disease
ClinicalTrials.gov recordGonadotroph Adenomas
ClinicalTrials.gov recordCushing's Syndrome
ClinicalTrials.gov recordPituitary Adenomas, Prolactinomas
ClinicalTrials.gov recordPancreatic Neoplasm, Pituitary Neoplasm, Nelson Syndrome, Ectopic ACTH Syndrome
ClinicalTrials.gov recordAcromegaly
ClinicalTrials.gov recordInfertility, Ovulation Induction
ClinicalTrials.gov recordNon-functioning Pituitary Adenoma
ClinicalTrials.gov recordPituitary Tumors
ClinicalTrials.gov recordCushing's Disease, Cushing's Syndrome
ClinicalTrials.gov recordPituitary Adenoma
ClinicalTrials.gov recordCushing's Disease
ClinicalTrials.gov recordNon-functioning Pituitary Adenomas, Prolactinomas
ClinicalTrials.gov recordAnovulation, Oligo-ovulation, Hypothalamic-pituitary Dysfunction, Polycystic Ovarian Syndrome
ClinicalTrials.gov recordAcromegaly, Pituitary Gigantism
ClinicalTrials.gov recordAcromegaly
ClinicalTrials.gov recordCushings Disease
ClinicalTrials.gov recordPituitary Adenoma, Pituitary Diseases
ClinicalTrials.gov recordPituitary Tumor, Pain
ClinicalTrials.gov recordAcromegaly
ClinicalTrials.gov recordPituitary Neoplasms
ClinicalTrials.gov recordPituitary Tumor, ACTH-producing Pituitary Tumour
ClinicalTrials.gov recordRecurrent Pituitary Adenomas
ClinicalTrials.gov recordPituitary Tumors
Treatment of Recurrent Pituitary Tumors
BYNFEZIA PEN is a s o matostatin analogue indicated: Acromegaly : To reduce blood levels of growth hormone (GH) and insulin growth factor 1 (IGF-1; somatomedin C) in acromegaly patients who have had inadequate response to or cannot be...
DailyMed labelINDICATIONS AND USAGE Ovidrel ® PreFilled Syringe (choriogonadotropin alfa injection) is indicated for the induction of final follicular maturation and early luteinization in infertile women who have undergone pituitary desensitization...
DailyMed labelINDICATIONS AND USAGE FOR CENTRAL PRECOCIOUS PUBERTY (For Endometriosis, See Reverse Side ) SYNAREL is indicated for treatment of central precocious puberty (CPP) (gonadotropin-dependent precocious puberty) in children of both sexes....
DailyMed label